Codagenix
Codagenix is a clinical-stage biotechnology company developing live-attenuated viral vaccines and cancer virotherapeutics using proprietary codon deoptimization technology, serving global health, oncology, and animal health markets via partnerships with WHO, PATH, Serum Institute of India, and the US Department of Defense.
- Company typePrivate
- Founded2015
- HeadquartersFarmingdale, United States
- Headcount1–10
- GTM typeB2B
- OfferingHardware or Manufacturing
Codagenix firmographics
Firmographics- Name
- Codagenix
- Legal name
- Codagenix, Inc.
- Website
- https://codagenix.com
- Company type
- Private
- Founded year
- 2015
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Codagenix is a clinical-stage biotechnology company developing live-attenuated viral vaccines and cancer virotherapeutics using proprietary codon deoptimization technology, serving global health, oncology, and animal health markets via partnerships with WHO, PATH, Serum Institute of India, and the US Department of Defense.
- Ownership category
- akta.pro rank
Codagenix industry classification
Industry- Product category
- Vaccines
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
- akta.pro secondary industries
- Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens) (HLAAAEAC), Clinical Development & Regulatory for Vaccines (trials, pharmacovigilance, lot release) (HLAAAEAK), Veterinary Vaccines (Biologics) (HLAMAEAL), Vaccine R&D, Clinical/Field Trials & Regulatory Affairs (HLAMAKAM)
Keywords
Where Codagenix is headquartered
LocationHeadquarters
- HQ city
- Farmingdale
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Codagenix business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Government Research Contracts and Grants: Funding from US Department of Defense for dengue vaccine development ($4.4M and $5.88M awards), supporting Phase 1 trials and clinical development.
- Series B Extension Funding: Venture capital funding round led by Serum Institute of India with participation from Euclidean Capital and Adjuvant Capital for clinical development of vaccines and oncology programs.
- Strategic Partnerships and Licensing: Collaborations with WHO, PATH, Serum Institute of India, and Gates Foundation for vaccine development, manufacturing, and global delivery.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels4 records
Codagenix product offering
Product offeringCore offering
Codagenix develops live-attenuated viral vaccines and cancer virotherapeutics using its proprietary codon deoptimization platform, which uses synthetic biology and machine learning to design hundreds of precise genetic edits into viral genomes. The company sells investigational vaccine candidates and virotherapeutic products for infectious diseases, oncology, and animal health to government agencies, global health organizations, and via co-development partnerships with manufacturers such as Serum Institute of India.
Product overview
Codagenix is a clinical-stage biotechnology company that has developed a proprietary synthetic biology-driven platform combining live-attenuated virus design with codon deoptimization technology. The company's product portfolio spans three core areas: (1) Infectious Disease Vaccines including CDX-DENV (dengue), CodaVax-RSV, CodaVax-H1N1 (influenza/pandemic), CoviLiv (COVID-19), Polio nOPV vaccine candidates, Yellow Fever, and CDX-ZiKV (Zika); (2) Cancer Virotherapeutics including CodaLytic for breast cancer and CDX-Onc for solid tumors; and (3) Animal Health Vaccines for farm animals (swine, poultry, cattle) and companion animals (canine). The platform enables rapid design and development of vaccine candidates, going from genetic sequence to viable candidate in weeks, with hundreds of intentionally placed genetic edits ensuring genetic stability.
Differentiator
Problem solved
Functional benefit
Brands
- CodaVax: Live-attenuated vaccine platform for RSV and influenza
- CoviLiv
- CodaLytic
- CDX-DENV
- CDX-ZiKV
Products and services
- CDX-DENV (Dengue Vaccine) A tetravalent dengue vaccine candidate leveraging codon deoptimization to design fully-homologous, contemporary strains that demonstrate balanced safety and immunogenicity across all four dengue virus serotypes in primates. Targeted at the approximately 2.5 billion people living in dengue-endemic regions globally.
- CodaVax-RSV An intranasal respiratory syncytial virus (RSV) vaccine candidate that is genetically stable, induces meaningful T cell responses, and has demonstrated efficacy against wild-type challenge in primates. Phase 1 trials have been completed in healthy adults with ongoing trials in toddlers and infants.
- CodaVax-H1N1 A pandemic influenza vaccine candidate designed as an intranasal, pan-type A live-attenuated virus vaccine demonstrating cross-protection in animal models, including against highly pathogenic H5N1 strains.
- CoviLiv A live-attenuated intranasal COVID-19 vaccine candidate that safely enables a broad antibody and T-cell immune response, developed in partnership with the World Health Organization and Serum Institute of India for global delivery to places in need.
- Polio (nOPV) Vaccine Candidates Novel oral poliovirus vaccine candidates (nOPV) modified using proprietary synthetic biology technology to reduce recombination risk with other enteroviruses, enhancing genetic stability compared to traditional Sabin oral polio vaccines. The nOPV2 platform has been deployed in over 1.8 billion doses globally during outbreak response with an estimated 80% reduction in emergence of new type 2 variant polio strains.
- Yellow Fever Vaccine A synthesized vaccine strain targeting yellow fever, a mosquito-borne viral disease with expanding geographic threat, designed for clinical development using an FDA-accepted surrogate endpoint for accelerated approval.
- CDX-ZiKV (Zika Vaccine) A Zika virus vaccine candidate redesigned using Codagenix's platform to produce a product that is safe and immunogenic in primates, addressing the mosquito-borne virus associated with microencephaly in infants.
- CodaLytic An influenza-based virotherapeutic candidate and Codagenix's lead oncology product for breast cancer, designed to modulate the tumor microenvironment through multiple mechanisms, triggering anti-tumor immune responses in preclinical models.
- CDX-Onc (Solid Tumors) A virotherapeutic platform targeting solid tumors, leveraging the codon deoptimization platform to construct target-specific immunotherapies focusing on immunologically cold tumors, broadening and deepening patient populations benefiting from established immunotherapies.
- Farm Animal Vaccines Vaccines for agricultural animals including swine, poultry, and cattle, targeting viral and bacterial infections to reduce agricultural losses and empower the agricultural community to reduce antibiotic use in production animals.
- Companion Animal Vaccines Vaccines for companion animals including canine, providing better protection against common and emerging diseases to increase healthy life years and improve quality of life for pets and owners.
Quantifiable outcome
- 80% reduction in new type 2 circulating vaccine-derived poliovirus emergences with nOPV2 compared to traditional Sabin OPV2
- +2 more outcomes
Companies that use Codagenix
Customer profileNamed customers2 records
Segments3 records
Ideal customer profiles5 records
Codagenix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature3 records
Codagenix partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core and foundational.
- PATHcoreCollaboration agreement funded by Gates Foundation to apply proprietary synthetic biology technology to fortify novel oral poliovirus vaccine (nOPV) strains against recombination with other enteroviruses, reducing risk of emergence of potentially neurovirulent vaccine-derived polioviruses. Codagenix will develop nOPV-maxSD strains with intent to establish in vitro proof of concept.
- World Health OrganizationcorePartnership with WHO to develop, manufacture and deliver CoviLiv, a novel intranasal COVID-19 vaccine candidate, to places in need around the world.
- Serum Institute of IndiacorePartnership with Serum Institute of India to manufacture and deliver CoviLiv COVID-19 vaccine candidate globally. Serum Institute also led the $25M Series B extension funding round.
- Stony Brook UniversityfoundationalTechnology origin: Codagenix was founded based on technology developed in the laboratory of National Academy of Science member Dr. Eckard Wimmer at Stony Brook University.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Codagenix competitors and assessment
Company assessmentBroad incumbents
- Moderna: Large mRNA platform company with approved COVID-19 vaccine and clinical-stage RSV, influenza, and pandemic preparedness programs — competes with Codagenix's infectious disease pipeline and has substantially greater resources.
- Bharat Biotech: Large global vaccine manufacturer (rotavirus, polio, typhoid) with strong ties to global health organizations, comparable to Codagenix's strategic partner ecosystem including Serum Institute of India.
Direct peers
- Tonix Pharmaceuticals: Clinical-stage developer of live virus vaccines (e.g., horsepox-based COVID-19 vaccine platform) that, like Codagenix, uses attenuated viral platforms for infectious disease prevention.
- Vaccitech: Clinical-stage viral vector vaccine developer (MERS, HPV, hepatitis B) that, like Codagenix, targets infectious disease with a platform-based approach and pursues global health partnerships.
- Vaxart: Clinical-stage developer of oral vaccines (including RSV and COVID-19 candidates) using a non-replicating viral vector platform — competes with Codagenix's intranasal live-attenuated programs in the same indications.
- CureVac: mRNA vaccine developer competing with Codagenix in influenza, COVID-19, and RSV, representing the alternative vaccine modality (mRNA) that Codagenix positions its live-attenuated platform against.
- Meissa Vaccines: Clinical-stage biotech developing live-attenuated vaccines for RSV and other respiratory viruses, sharing Codagenix's live-attenuated vaccine approach and intranasal delivery focus.
- Novavax: Clinical-to-commercial stage vaccine developer with recombinant nanoparticle COVID-19 and influenza vaccines, competing for the same global health and pandemic preparedness markets.
Emerging players
- CaroGen Corporation: Early-stage virotherapeutics company developing codon-modified viral immunotherapies for cancer and infectious disease — directly comparable to Codagenix's synthetic virology platform, though focused on different therapeutic areas.
- Vyriad: Clinical-stage oncolytic virus developer building engineered virotherapeutics for solid tumors — competes with Codagenix's CodaLytic and CDX-Onc oncology programs in the same immunotherapy space.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Codagenix social profiles
Digital presenceCodagenix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Codagenix leadership team
Management profileNumber of profiles
Profiles9 records
Codagenix funding detail
Funding detailFunding overview
Funding rounds12 records
Investors9 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Codagenix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Codagenix
What does Codagenix do?
Codagenix develops live-attenuated viral vaccines and cancer virotherapeutics using its proprietary codon deoptimization platform, which uses synthetic biology and machine learning to design hundreds of precise genetic edits into viral genomes. The company sells investigational vaccine candidates and virotherapeutic products for infectious diseases, oncology, and animal health to government agencies, global health organizations, and via co-development partnerships with manufacturers such as Serum Institute of India.
Is Codagenix a public or private company?
Codagenix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Codagenix founded?
Codagenix was founded in 2015. It employs 1 to 10 people.
Where is Codagenix based?
Codagenix is headquartered in Farmingdale, United States, in the North America region.
How does Codagenix make money?
Three revenue lines are on record. Government Research Contracts and Grants are the primary driver. The others are series B Extension Funding and strategic Partnerships and Licensing.
Who are Codagenix's main competitors?
Broad incumbents on record are Moderna and Bharat Biotech. Direct peers are Tonix Pharmaceuticals, Vaccitech, Vaxart, CureVac, Meissa Vaccines and Novavax. Emerging players are CaroGen Corporation and Vyriad.
Does Codagenix have an API?
No public API is recorded for Codagenix.
What industry is Codagenix in?
Codagenix's product category is Vaccines. Its primary akta.pro industry code is HLAAAEAD, Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA), with a secondary code of HLAAAEAC, Infectious Disease & Pandemic Preparedness Vaccines (emerging pathogens). Its NAICS code is 325414 and its SIC code is 2836.